Histogen, Inc.

100 articles with Histogen, Inc.

• Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/29/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the Canaccord Genuity 41st Annual Growth Conference.

• Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

  7/28/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.

• Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

  6/30/2021

  Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST 003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.

• 

  Clinical Catch-Up: June 21-25

  6/28/2021

  It was a busy week for clinical trial news. Here’s a look.

• Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

  6/22/2021

  Histogen Inc. (NASDAQ: HSTO), and its partner Amerimmune LLC, today announced top line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

• Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  6/9/2021

  Histogen Inc. announced the closing of its previously announced registered direct offering for the issuance and sale of 5,977,300 shares of its common stock, at a purchase price of $1.10 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

• Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  6/7/2021

  Histogen Inc. (Nasdaq: HSTO), today announced that it has entered into definitive agreements with several institutional and accredited investors, for the purchase and sale of 5,977,300 shares of its common stock,

• Histogen Provides Update on its Development Programs and Pipeline Focus

  6/3/2021

  Histogen Inc. announced an update on its pipeline focus following a strategic evaluation of its regenerative medicine platform technology development programs with the goal of focusing on high value orthopedic indications, creating pipeline synergies and maximizing resources in an effort to further drive long-term shareholder value.

• Histogen and Amerimmune Report Publication on Emricasan in COVID-19Study Demonstrated Potential In Vitro Benefit in Acute and Long-Haul Phases of COVID-19

  5/19/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function and its partner, Amerimmune, LLC, today reported the publication of the potential utility of emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology.

• Histogen Reports First Quarter 2021 Earnings and Provides Business Update

  5/13/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the first quarter ended March 31, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update

  4/28/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Thursday, May 13, 2021.

• Histogen to Present at the 20th Annual Needham Virtual Healthcare Conference

  3/30/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the 20th Annual Needham Virtual Healthcare Conference.

• Histogen Appoints Rochelle Fuhrmann to Board of Directors

  3/25/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function has appointed Rochelle Fuhrmann to its Board of Directors and Chairperson of the Audit Committee. In addition, current director Stephen Chang, Ph.D. will be resigning from the Board.

• Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 PatientsTopline Results Expected in the Second Quarter of 2021

  3/16/2021

  Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

• Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

  3/15/2021

  Histogen Inc. (NASDAQ: HSTO), today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all clinical hold questions and can proceed with initiation of the planned Phase 1/2 clinical trial of HST-003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003)

• Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

  3/11/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on its clinical pipeline and other corporate developments.

• Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.

  3/10/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function has appointed Susan R. Windham-Bannister, Ph.D. to its Board of Directors.

• Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update

  3/4/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2020 will be released after the close of market on Thursday, March 11, 2021.

• Histogen to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

  3/2/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced it will present at the H.C. Wainwright Global Life Sciences Virtual Conference.

• Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

  2/16/2021

  HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S.